Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells by Schuberth, Petra C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Treatment of malignant pleural mesothelioma by fibroblast activation
protein-specific re-directed T cells
Schuberth, Petra C; Hagedorn, Christian; Jensen, Shawn M; Gulati, Pratiksha; van den Broek, Maries;
Mischo, Axel; Soltermann, Alex; Jüngel, Astrid; Marroquin Belaunzaran, Osiris; Stahel, Rolf; Renner,
Christoph; Petrausch, Ulf
Abstract: INTRODUCTION: Malignant pleural mesothelioma (MPM) is an incurable malignant disease,
which results from chronic exposition to asbestos in at least 70% of the cases. Fibroblast activation
protein (FAP) is predominantly expressed on the surface of reactive tumor-associated fibroblasts as well
as on particular cancer types. Because of its expression on the cell surface, FAP is an attractive target
for adoptive T cell therapy. T cells can be re-directed by retroviral transfer of chimeric antigen receptors
(CAR) against tumor-associated antigens (TAA) and therefore represent a therapeutic strategy of adop-
tive immunotherapy. METHODS: To evaluate FAP expression immunohistochemistry was performed
in tumor tissue from MPM patients. CD8+ human T cells were retrovirally transduced with an anti-
FAP-F19-￿CD28/CD3￿-CAR. T cell function was evaluated in vitro by cytokine release and cytotoxicity
assays. In vivo function was tested with an intraperitoneal xenograft tumor model in immunodeficient
mice. RESULTS: FAP was found to be expressed in all subtypes of MPM. Additionally, FAP expression
was evaluated in healthy adult tissue samples and was only detected in specific areas in the pancreas,
the placenta and very weakly for cervix and uterus. Expression of the anti-FAP-F19-￿CD28/CD3￿-CAR
in CD8+ T cells resulted in antigen-specific IFN￿ release. Additionally, FAP-specific re-directed T cells
lysed FAP positive mesothelioma cells and inflammatory fibroblasts in an antigen-specific manner in
vitro. Furthermore, FAP-specific re-directed T cells inhibited the growth of FAP positive human tumor
cells in the peritoneal cavity of mice and significantly prolonged survival of mice. CONCLUSION: FAP
re-directed CD8+ T cells showed antigen-specific functionality in vitro and in vivo. Furthermore, FAP
expression was verified in all MPM histotypes. Therefore, our data support performing a phase I clinical
trial in which MPM patients are treated with adoptively transferred FAP-specific re-directed T cells.
DOI: 10.1186/1479-5876-11-187
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81960
Veröffentlichte Version
 
 
Originally published at:
Schuberth, Petra C; Hagedorn, Christian; Jensen, Shawn M; Gulati, Pratiksha; van den Broek, Maries;
Mischo, Axel; Soltermann, Alex; Jüngel, Astrid; Marroquin Belaunzaran, Osiris; Stahel, Rolf; Renner,
Christoph; Petrausch, Ulf (2013). Treatment of malignant pleural mesothelioma by fibroblast activation
protein-specific re-directed T cells. Journal of Translational Medicine, 11:187. DOI: 10.1186/1479-5876-
11-187
2
RESEARCH Open Access
Treatment of malignant pleural mesothelioma by
fibroblast activation protein-specific re-directed
T cells
Petra C Schuberth1, Christian Hagedorn1, Shawn M Jensen2, Pratiksha Gulati1, Maries van den Broek1, Axel Mischo1,
Alex Soltermann3, Astrid Jüngel4, Osiris Marroquin Belaunzaran1, Rolf Stahel1, Christoph Renner1,5†
and Ulf Petrausch5*†
Abstract
Introduction: Malignant pleural mesothelioma (MPM) is an incurable malignant disease, which results from chronic
exposition to asbestos in at least 70% of the cases. Fibroblast activation protein (FAP) is predominantly expressed
on the surface of reactive tumor-associated fibroblasts as well as on particular cancer types. Because of its
expression on the cell surface, FAP is an attractive target for adoptive T cell therapy. T cells can be re-directed by
retroviral transfer of chimeric antigen receptors (CAR) against tumor-associated antigens (TAA) and therefore
represent a therapeutic strategy of adoptive immunotherapy.
Methods: To evaluate FAP expression immunohistochemistry was performed in tumor tissue from MPM patients.
CD8+ human T cells were retrovirally transduced with an anti-FAP-F19-ΔCD28/CD3ζ-CAR. T cell function was
evaluated in vitro by cytokine release and cytotoxicity assays. In vivo function was tested with an intraperitoneal
xenograft tumor model in immunodeficient mice.
Results: FAP was found to be expressed in all subtypes of MPM. Additionally, FAP expression was evaluated in
healthy adult tissue samples and was only detected in specific areas in the pancreas, the placenta and very weakly
for cervix and uterus. Expression of the anti-FAP-F19-ΔCD28/CD3ζ-CAR in CD8+ T cells resulted in antigen-specific
IFNγ release. Additionally, FAP-specific re-directed T cells lysed FAP positive mesothelioma cells and inflammatory
fibroblasts in an antigen-specific manner in vitro. Furthermore, FAP-specific re-directed T cells inhibited the growth
of FAP positive human tumor cells in the peritoneal cavity of mice and significantly prolonged survival of mice.
Conclusion: FAP re-directed CD8+ T cells showed antigen-specific functionality in vitro and in vivo. Furthermore,
FAP expression was verified in all MPM histotypes. Therefore, our data support performing a phase I clinical trial in
which MPM patients are treated with adoptively transferred FAP-specific re-directed T cells.
Introduction
Malignant pleural mesothelioma (MPM) is a rare solid
organ tumor, which originates from malignant transformed
cells of the mesothelium [1]. A causal link to environmen-
tal factors has been established as at least 70% of MPM pa-
tients have a definite record of chronic asbestos exposure
[2]. MPM is considered an incurable disease with a median
survival of 2 years even when intensive multi-modality
treatment is performed [3-5]. Therefore, new therapeutic
options are desperately needed.
Adoptive transfer of modified (re-directed) autologous
T cells is a promising therapeutic strategy and objective
responses were observed in preliminary clinical trials
[6]. Re-directed T cells are (autologous) T cells that are
retrovirally transduced to express a chimeric antigen recep-
tor (CAR) specific for a target on the cell surface. CARs
contain a single-chain Fv (scFv)-based molecule, which
is specific for the target and coupled to T cell-specific
signaling moieties such as CD28 and CD3ζ. The general
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functionality of these CARs is documented widely by re-
cent literature [7]. The most striking success was ob-
served in B cell lymphoma patients when CD19 was
used as an immunological target [8]. However, also
in solid cancer types such as ovarian cancer [9] and
neuroblastoma [10] adoptive T cell transfer was tested. Re-
cently, we successfully generated peptide-specific re-
directed T cells targeting NY-ESO-1 [11]. We tested
different signaling domains of the chimeric antigen
receptors (CARs) and could observe in vivo and in vitro
immunological functionality [12].
To treat MPM with re-directed T cells, we set out to
identify a surface protein that is universally expressed by
the majority of MPM subtypes (epithelioid, sarcomatoid
and biphasic). Fibroblast activation protein (FAP) was
suggested to be a potential target antigen since FAP is
widely expressed by various epithelial and mesenchymal
cancer types [13]. FAP expression has been studied ex-
tensively by immunohistochemistry in the past [14] and
is known to differ between cell types and even within
the tumor tissue. Two patterns of expression are most
frequently found: 1) FAP expression by cancer associated
fibroblasts (CAFs) of the tumor stroma only (e.g. breast
or colorectal cancer [15]) or 2) by both the tumor stroma
and the tumor cells (e.g. sarcoma [16]). Altogether, FAP is
expressed in about 90% of most common cancer types like
breast, lung and colorectal cancer [17]. Its expression is
also associated with chronic inflammation, tissue remodel-
ing [18] and immune modulation in the tumor tissue [19].
We show here that FAP is expressed in all three major
MPM histotypes, namely the epithelioid, sarcomatoid and
the intermediate called biphasic.
FAP has been validated as target antigen in oncology
by a monoclonal antibody called F19 (humanized ver-
sion: sibrotuzumab) in different phase I/II clinical trials
[20,21]. The antibody recognizes exclusively non-degraded
human FAP. F19 accumulated specifically in the tumor tis-
sue [22]; however, the clinical effect was marginal. The re-
sults indicated that the sole use of an antibody was not
sufficient to induce a meaningful immunological anti-
tumor response. Therefore, F19 was not further developed
for clinical use [21].
We developed re-directed T cells with a CAR consisting
of a scFv of the FAP-specific F19 antibody, a CD28
signaling domain lacking the lck binding moiety [23]
and a CD3ζ signaling domain. Our rational to develop
FAP-specific re-directed T cells based on the F19 anti-
body was to utilize its already clinically proven specifi-
city to target FAP positive tumor tissue combined with
the immunological effector function of T cells. As observed
by others our previous results clearly indicated increased
antigen-specific function of re-directed T cells when
the CAR contained a CD28 signaling domain [12,24].
Therefore, we decided to generate a second generation
CAR with a co-stimulating signal provided by the CD28
domain. For the first time we show here that re-directed
T cells specific for FAP are cytotoxic towards FAP posi-
tive targets in vitro and control xenografted human FAP
positive tumors in vivo.
Material and methods
Cell lines
293T and MSTO-211H were purchased from ATCC
(Manassas, VA). HT1080FAP are HT1080 cells stably
transfected with human FAP and HT1080PA are mock-
transfected HT1080 cells [25]. T2-1B cells are HLA-A
*02:01-positive T2 cells stably transfected with the HLA-
A*02:01-restricted NY-ESO-1 peptide 157–165 [26]. Tumor
cell lines were cultivated in standard R10 media (RPMI1640
GlutaMax supplemented with 10% fetal bovine serum
(FBS) (v/v), 50 U/ml penicillin and 50 μg/ml streptomycin;
all obtained from Invitrogen (Karlsruhe, Germany)).
For the culture of transfected HT1080 and T2 cells,
200 μg/ml G418 (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland) or 2.5 μg/ml Hygromycin B (Invitrogen,
Karlsruhe, Germany) was added, respectively.
To enable in vivo imaging, HT1080FAP and HT1080PA
cells were stably transfected with a D-firefly lucifer-
ase encoding plasmid (pGL4.26 plasmid, Promega,
Dübendorf, Switzerland which was kindly provided by
Martin Pruschy, University Hospital Zurich, Switzerland)
using Fugene transfection reagent (Roche Diagnostics
GmbH, Mannheim, Germany) according to the manufac-
turer’s protocol. Forty-eight hours after transfection cells
were submitted to selection using 150 μg/ml Hygromycin
B. Cells were cloned by limited dilution and luciferase
expression was monitored using Bright-Glo™ Luciferase
Assay System and a GloMax Microplate Luminometer
(both Promega, Madison, WI) according to the manufac-
turer’s protocol. Clones with luciferase activity underwent
two more rounds of limited dilution followed by further
testing for luciferase activity. Finally, a stable HT1080FAP-
luc and HT1080PA-luc clone were selected that exhibited
high luciferase activity and maintained this over months
even when cultured in the absence of Hygromycin B. The
resultant HT1080FAP-luc and HT1080PA-luc cells were
cultivated in standard R10 media supplemented with
200 μg/ml G418 and 150 μg/ml Hygromycin B.
Rheumatoid arthritis synovial fibroblasts originating
from tissues obtained during joint replacement sur-
gery (Schulthess Clinic, Zurich, Switzerland) were isolated
for cell cultures as described previously [27]. Briefly,
synovial tissues were digested with dispase at 37°C for
60 minutes. After washing, cells were grown in Dulbecco’s
MEM NUT MIX-F12 (Invitrogen, Karlsruhe, Germany)
supplemented with 10% FBS, 50 U/ml penicillin, 50 μg/ml
streptomycin and 10 mM HEPES (Invitrogen, Karlsruhe,
Germany).
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Antibodies and reagents
Antibodies for flow cytometry were purchased from
eBioscience (San Diego, CA) (anti-human CD8a-FITC),
Invitrogen (Karlsruhe, Germany) (LIVE⁄DEAD Fixable Aqua
Dead Cell Stain Kit) and Southern Biotech (Birmingham,
AL) (anti-human IgG-PE). Analysis of FAP expression
was performed using the humanized anti-F19 antibody
[20] (kindly provided by Andrew Scott, Ludwig Insti-
tute for Cancer Research, Australia), whereas MabThera
(Rituximab; anti CD20 mAb; Roche Pharma AG, Reinach,
Switzerland) was used as a negative control antibody. Both
antibodies were directly labeled with Alexa Fluor 647
(Alexa Fluor® 647 Antibody Labeling Kit; Invitrogen,
Karlsruhe, Germany) according to the manufacturer’s
protocol. Murine F19 antibody [25] (kindly provided by
Andrew Scott, Ludwig Institute for Cancer Research,
Australia) was used as primary antibody for immunohisto-
chemistry staining, and the murine HD6 monoclonal anti-
body served as a control antibody [28]. A biotin-labeled
goat anti mouse IgG (Fcγ fragment specific) was used as
secondary antibody (Jackson ImmunoResearch, Suffolk,
UK). Recombinant human FAP was kindly provided
by Andrew Scott, Ludwig Institute for Cancer Research,
Australia.
Generation of the FAP-specific chimeric antigen
receptor (CAR)
The variant heavy and the variant light chain of human-
ized F19 [21] have been converted into a scFv fragment
and were flanked with NcoI and BamHI restriction sites.
This construct was cloned into the pBullet vector [29]
containing a human ΔCH2/CH3 domain, a ΔCD28 [23]
and a CD3ζ signaling domain (kindly provided by Hinrich
Abken, University of Cologne, Germany). The human
CH2/CH3 domain has been modified to reduce FcγR
binding and thereby minimizing the risk of off-target
T cell activation by CAR binding to FcγR+ cells [30]. Fur-
thermore, the CD28 binding domain for lck was corrupted
by site directed mutagenesis to avoid IL-2 release and sub-
sequent persistence of Treg cells [23].
The resulting chimeric antigen receptor construct was
termed anti-FAP-F19-ΔCD28/CD3ζ. Anti-NY-ESO-1-
T1-ΔCD28/CD3ζ recognizing the HLA-A*02:01/ NY-
ESO-1157-165 peptide complex served as a control construct
[12]. It displays the same genetic modifications in the
downstream CH2/CH3 and CD28 lck domains.
Retroviral transduction of peripheral blood CD8+ T cells
Retroviral transduction of human peripheral CD8+ T
cells was performed as previously described [12] with
following minor modifications. CD8+ T cells were purified
from healthy donor buffy coats using anti-CD8 labeled
magnetic beads and MACS technology (Miltenyi, Bergisch
Gladbach, Germany). Positive selection with anti-human
CD8 microbeads typically resulted in a ≥ 95% pure CD8+
population. CD8+ T cells were subsequently activated with
CD3/CD28 human T cell expander beads (Invitrogen,
Germany) at a bead to cell ratio of 1:5 and 100 IU/ml IL-2
(ImmunoTools, Friesoythe, Germany) in standard R10
media for 48 h. Activated CD8+ T cells were retrovirally
transduced for 48 hours in the presence of 100 IU/ml
IL-2 by co-cultivation with 293T cells that were transi-
ently producing high titers of infectious retrovirus car-
rying the genomic information of the chimeric antigen
receptors. CD8+ T cells were expanded for 2 more days in
R10 plus 100 IU/ml IL-2 before harvest and subsequent
application in experiments.
Flow cytometry
Flow cytometry was carried out as described previously
[12]. Live/dead staining was performed using the LIVE/
DEAD fixable Aqua Dead Cell Stain Kit according to the
manufacturer’s protocol. BrdU Proliferation assay were
performed with the FITC BrdU flow kit (BD Pharmingen,
San Diego, CA) according to the manufacturer’s instruc-
tion. Flow cytometric measurements were performed using
a FACSCanto II or FACSCalibur machine (BD Biosciences,
San Diego, CA). Data were analyzed using FlowJo software
(Tree Star, Ashland, OR).
Cytokine assays
Cytokine production was assessed by sandwich ELISA
assays. Supernatants of co-cultivated effector and target
cells were collected after 24 hours of incubation. IFNγ
and IL-2 levels were detected using BD OptEIA set
human IFNγ and BD OptEIA set human IL-2 kits, re-
spectively, according to the manufacturer’s instruction
(BD Biosciences, San Diego, CA).
Immunohistochemistry
To study potential off-target sites of FAP re-directed T
cells, we purchased frozen tissue arrays that contained
human adult normal tissue (BioChain, Newark, CA) and
stained them for FAP expression. To study expression of
FAP in MPM, a total of 9 fresh-frozen samples from ma-
lignant pleural mesothelioma patients were retrieved
from the biobank of the Institute of Surgical Pathology,
University Hospital Zurich.
To perform immunohistochemistry acetone-fixed tis-
sue slides were developed employing the Vectastain ABC
Kit Peroxidase Mouse IgG (VECTOR LABORATORIES,
Burlingame, CA) according to the manufacturer’s proto-
col with minor modifications. Briefly, slides were addition-
ally incubated with an avidin and a biotin block (both
VECTOR LABORATORIES, Burlingame, CA) for 10 min
at RT. Two μg/ml murine F19 or murine HD6 antibody as
negative control in 20% of blocking buffer (10% rabbit
serum (VECTOR LABORATORIES, Burlingame, CA), 5%
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milk powder (Roth, Karlsruhe, Germany) in PBS) were
added as primary antibody overnight at 4°C. The sec-
ondary biotin-goat anti mouse Fc antibody was diluted
1:2000 in 20% of blocking buffer. ImmPACT DAB, SK-
4105 (VECTOR LABORATORIES, Burlingame, CA) was
used as peroxidase substrate kit according to the manufac-
turer’s protocol.
The slides were analyzed with a high-speed wide field
fluorescence microscope Leica LX and pictures were
recorded using a Leica DFC 350 FX camera system (both
Leica Microsystems, Heerbrugg, Switzerland).
Europium release assay
Specific cytotoxicity of re-directed T cells was analyzed
by a europium release assay (Perkin Elmer, Waltham, MA)
as previously described [12]. HT1080FAP-luc, HT1080PA-
luc, MSTO-211H, T2-1B and primary rheumatoid fibro-
blasts served as target cells for anti-FAP-F19-ΔCD28/CD3ζ
and anti-NY-ESO-1-T1-ΔCD28/CD3ζ re-directed T cells.
All cell lines were labeled with 2,2’:6’,2”-terpyridine-6,6”-
dicarboxylic acid acetoxymethylester (BATDA) for 30 min
at 37°C. Target cells were seeded at a density of 104
cells per 96-round bottom-well and co-cultured with
effector cells at different effector:target ratios for 4 h
at 37°C in R10 media followed by supernatant analyses
in a time-resolved Victor2 flourometer (Perkin Elmer,
Waltham, MA). The specific cytolysis of target cells (%)
was calculated by the equation: 100x[experimental release
(counts) − spontaneous release(counts)]/[maximum release
(counts) − spontaneous release(counts)]
Therapy of xenografted FAP+ human tumors
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice, commonly known
as NOD.scid.γcKO (NSG), were originally obtained from
Jackson Laboratories (Bar Harbor, ME, USA), bred and
maintained at the University Hospital Zurich under spe-
cific pathogen-free conditions. HT1080FAP-luc tumor cells
(106 cells per mouse) were co-injected intraperitoneally
with re-directed T cells at an effector to target ratio of 5:1.
Tumor burden was monitored by body weight measure-
ments and in vivo bioluminescence imaging. For that
purpose, mice were anesthetized with 2% isoflurane and
i.p. injected with 150 mg/kg D-Luciferin (Caliper Life
Sciences, Hopkinton, MA) and signals were visualized
using IVIS®200 Caliper (Caliper Life Sciences, Hopkinton,
MA). Monitoring of mice was started immediately after
D-Luciferin injection and lasted up to 20 min to obtain
the peak photon emission of each animal. Biolumines-
cence signals were collected and converted to photons/
second/cm2/steradian in order to normalize each setting
for F-stop, exposure time, binning and animal size using
Living Image 3.2 (Caliper Life Sciences, Hopkinton, MA).
A constant region of interest was designated around the
torso of each animal in order to avoid any incoherence.
For imaging purposes, a pseudocolor map representing
light intensity was superimposed over a whole-body image.
Age-matched mice were used for all experiments. Tumor-
bearing mice were euthanized if their body weight in-
creased or decreased more than 15% if compared to the
weight of non-diseased, age-matched mice or if mice were
confined in their normal behavior by tumor growth. Ani-
mal experiments were performed according to Swiss fed-
eral and cantonal laws on animal protection.
Statistical analysis
Data were analyzed with Graph Pad Prism version 5.00
for Windows (GraphPad Software, San Diego, CA). Stu-
dent’s unpaired 2-tailed t-tests were performed between
two groups of interest. Survival analysis was performed
employing Kaplan Meier survival curves and significance
between two variables was calculated using the log-rank
test.
Results
Malignant pleural mesothelioma expressed fibroblast
activation protein in the tumor-associated stroma and on
tumor cells
We analyzed the three distinct histologic subtypes of
malignant pleural mesothelioma from a total of 18 pa-
tient biopsies for FAP expression. The MPM histosubtype
was determined by a panel of positive and negative im-
munohistochemistry (IHC) markers (Calretinin, CK5/6
und TTF1) and morphology. Different cell types in the
biopsies were identified by morphology. Staining for
FAP was scored by the reference pathologist of our in-
stitution (A.S.) in a three-tiered system (+: faint, ++
moderate, and +++ strong).
Eight out of eight epithelioid MPM specimens showed
faint to strong FAP expression on tumor cells and a mod-
erate to strong expression on stromal cells (Figures 1a,b).
Two out for four sarcomatoid MPM samples displayed
moderate membranous expression of FAP on tumor cells
as well as on stromal cells (Figures 1c,d). All six biphasic
MPM samples showed moderate to strong FAP expression
on the tumor cells and a strong expression in the stromal
compartment (Figures 1e,f). In total, we discovered FAP
expression on tumor cells and stroma in 16 out of 18 pa-
tient MPM samples.
To evaluate FAP expression in healthy adult tissue
we screened 20 organ specimens for FAP expression
to determine possible targets of toxic side-effects (adrenal,
ovary, pancreas, thyroid, uterus, cervix, breast, placenta,
cerebrum, cerebellum, lung, spleen, heart, skin, skel-
etal muscle, kidney, stomach, small intestine, liver
and salivary gland). Specific FAP expression was only
present in specific areas of the pancreas and placenta
and very weakly for cervix, and uterus (Additional file 1:
Figure S1).
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Generation of FAP-specific, re-directed CD8+ T cells
We generated re-directed T cells expressing a CAR
consisting of a single-chain Fv (scFv) molecule recogniz-
ing FAP. The scFv is linked to a modified human CH2/3
immunoglobulin domain to reduce FcRγ binding and a
ΔCD28 co-stimulatory domain which lacks the lck bind-
ing moiety. The last moiety of the construct is the CD3ζ
domain which facilitates intracellular signaling (anti-
FAP-F19-ΔCD28/CD3ζ). As a control construct we cloned
the scFv of the recently published anti-NY-ESO-1-T1-
CD28/CD3ζ in the Δ backbone which in the following is
termed anti-NY-ESO-1-T1-ΔCD28/CD3ζ [12]. A sche-
matic representation of the CAR re-directed T cells is given
in Additional file 1: Figure S2.
We isolated CD8+ T cells from human peripheral
blood and retrovirally transduced them to achieve cell
surface expression of CARs which was assessed by detec-
tion of the modified human CH2/3 immunoglobulin do-
main (hIgG) using flow cytometry. After transduction,
46.7% of anti-FAP-F19-ΔCD28/CD3ζ re-directed CD8+ T
cells stained for hIgG (Figure 2b) and 52.6% of CD8+ T
cells carried the anti-NY-ESO-1-T1-ΔCD28/CD3ζ CAR
(Figure 2c). Non-transduced CD8+ T cells did not stain
for hIgG (Figure 2a). The range of transduction efficiency
for anti-FAP-F19-ΔCD28/CD3ζ was 31.31 ± 10.69 (SD)
and for anti-NY-ESO-1-T1-ΔCD28/CD3ζ 32.55 ± 10.31
(SD) (Figure 2b,c). To investigate the functionality of the
generated re-directed T cells we co-cultivated effector
cells and target cells at a 1:1 ratio. Both constructs
showed antigen-specific IFNγ release (Figure 2d). Further-
more, to determine the effect of abrogating the lck-binding
domain, we activated CD8+ T cells expressing anti-
FAP-F19-ΔCD28/CD3ζ or anti-FAP-F19-CD28/CD3ζ
(intact lck-signaling) with recombinant human FAP.
Measurement of IL-2 release demonstrated a significant
reduction in IL-2 production in anti-FAP-F19-ΔCD28/
CD3ζ re-directed T cells. However, anti-FAP-F19-ΔCD28/
CD3ζ re-directed T cells secreted measurable basal
amounts of IL-2 (Figure 2f ). Since we observed reduced
IL-2 production we investigated the ability of anti-
FAP-F19-ΔCD28/CD3ζ re-directed T cells to proliferate
in the absence of exogenous IL-2. Up to day 6 during
antigen-specific stimulation the addition of exogenous
IL-2 did not increased the proliferation capacity of anti-
FAP-F19-ΔCD28/CD3ζ re-directed T cells (Figure 2f ).
To investigate the longevity of re-directed T cells with-
out cytokine support we analyzed the in vitro survival
of anti-FAP-F19-ΔCD28/CD3ζ re-directed T cells with
or without supplementation of 100 IU/ml IL-2 employing
live/dead staining of CD8+ T cells. The addition of
IL-2 led in all cases to sustained survival of 70–98%
CAR+ as well as CAR- T cells (Figure 2d) whereas no
IL-2 supplementation resulted in early loss of CAR+ T
cells starting around day 3 (Figure 2e). CAR- T cells
showed a high percentage of living cells out to day 8.
However, between day 8 and 12 all IL-2 deprived CD8
T cells were lost regardless of their transduction state
(Figure 2e).
FAP-specific, re-directed T cells lysed FAP positive
target cells
We performed europium cytotoxicity assays to deter-
mine antigen-specific cytotoxicity of the re-directed
T cells in vitro. Therefore, we used different target
cells that exhibited various levels of FAP expression.
As expected from FAP positive IHC of MPM specimens
the mesothelioma derived cell line MSTO-211H showed
FAP expression (Additional file 1: Figure S3c). The FAP
transduced cell line HT1080FAP-luc (Additional file 1:
Figures S3a,b) served as positive control. As expected
from previous reports [29] primary fibroblasts from
patients with active joint inflammation also stained
positive for FAP (Additional file 1: Figure S3e). We
employed as control cell lines HT1080PA-luc and T2-1B
known to be negative for FAP expression (Additional file 1:
Figures S3b,f and g). Importantly, co-cultivation of the
mesothelioma cell line MSTO-211H with anti-FAP-F19-
ΔCD28/CD3ζ re-directed T cells resulted in specific lysis
*
*
*
Figure 1 IHC of fresh-frozen malignant pleural mesothelioma
patient sections. A, c and e were stained with the FAP
recognizing murine F19 antibody, whereas b, d, f represent the
secondary system only. All three histosubtypes of MPM have been
analyzed: epithelioid (a, b), sarcomatoid (c, d) and bi-phasic (e, f).
Regions marked with * indicate areas of predominant tumor
cell location.
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of MSTO-211H cells in a dose dependent manner
(Figure 3a). In addition, HT1080FAP and primary fi-
broblasts were also specifically lysed (Figures 3b,c).
Anti-FAP-F19-ΔCD28/CD3ζ re-directed T cells exhib-
ited only background lysis when co-cultivated with
the FAP negative cell lines HT1080PA-luc and T2-1B
(Figures 3d,e). Anti-NY-ESO-1-T1-ΔCD28/CD3ζ re-
directed T cells did not recognize any target cell lines
besides T2-1B cells which express the HLA-A*02:01/
NY-ESO-1157-165 peptide complex as their specific tar-
get structure. These data show that FAP-specific re-
directed T cells specifically and efficiently lyse FAP
positive targets in vitro.
Adoptive therapy with anti-FAP-F19-ΔCD28/CD3ζ re-directed
T cells resulted in significant delay of FAP+ tumor outgrowth
in the peritoneum of NSG mice
Our findings above demonstrated a FAP-specific re-
direction of T cells in vitro and a moderate to high FAP
expression in MPM samples. The proposed clinical trial
is designed to inject re-directed T cells in the pleural
space [31]. However, as the pleural space is difficult to
assess in mice we established a model in the peritoneum
to mimic adoptive transfer of T cells in a body cavity.
Therefore, we evaluated the anti-tumor activity of FAP
specific re-directed T cells by establishing an i.p. tumor
model which constitutively expressed FAP as well as
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luciferase for in vivo detection of tumor cells. Injection
of HT1080FAP-luc cells into the peritoneum resulted in
progressively growing tumors and mice had to be eutha-
nized within three weeks in accordance to predefined
end-points (data not shown). HT1080FAP-luc cells and
FAP-re-directed T cells or NY-ESO-1-re-directed T cells
were co-injected i.p. and monitored by serial biolumines-
cent imaging as indicated (Figure 4a). A significant delay
and/or protection of tumor outgrowth was detected in
the group treated with anti-FAP re-directed T cells,
whereas the tumor grew progressively in the control
group injected with NY-ESO-1- re-directed T cells. In this
allogeneic setting of T cells and tumor cells, NY-ESO-1-
specific re-directed T cells displayed no specific anti-tumor
effect but prolonged the survival compared to the saline
control group (data not shown). Most importantly, there
was a significant difference between the anti-FAP and the
anti-NY-ESO-1 treated group from day 28 on (P = 0.041,
data not shown). In addition, the survival of the experi-
mental groups was monitored. Based on pre-defined end-
points in accordance with animal protection mice were
euthanized (Figure 4b). The survival after injection of anti-
FAP re-directed T cells was significantly longer compared
to the control group treated with anti-NY-ESO-1 re-
directed T cells (p = 0.007). Median 50% survival was
not reached in the group treated with anti-FAP re-directed
T cells.
Discussion
MPM is still a disease in which even the combination
of all three conventional branches of oncologic treat-
ment, surgery, chemotherapy and radiotherapy have to
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be considered a palliative attempt and other therapeutic
options have to be evaluated [32]. Beside therapies
targeting molecular pathways of the malignant cells
[33], immunotherapy is a novel therapeutic strategy to
fight MPM [34]. Most of the so far tested approaches
focus on the induction of an active-specific immune re-
sponse. As an alternative approach, passive adoptive
immune therapy could be proposed. Therefore, we inves-
tigated the potential therapeutic effect of FAP-specific re-
directed T cells as a new option for treatment of MPM.
All three histological subtypes of MPM demonstrated
FAP expression by the tumor stroma and by most tumor
cells. Garin-Chesa and colleagues had demonstrated FAP
expression in 7 MPM samples in the tumor stroma as
well as on tumor cells with variable FAP expression levels
[13]. T cells expressing anti-FAP CARs at high level were
generated by standard procedures and these re-directed
T cells were antigen-specific as characterized by their
specific in vitro killing of FAP positive mesothelioma
cells. To examine the therapeutic efficacy of FAP-specific
re-directed T cells in vivo, we adoptively transferred
re-directed T cells into the peritoneal cavity of mice
bearing FAP + tumors. In this setting, FAP-specific
re-directed T cells showed strong therapeutic potential,
preventing the growth of FAP + tumors and increasing sur-
vival of mice.
MPM derives from the mesothelial cell lineage of the
serous membranes of the pleura. This process causes a
chronic stimulation of the serous membranes resulting
in pleural effusion in the majority of clinical cases.
Since our first planned clinical protocol (manuscript
is published: Petrausch U, Schuberth PC, Hagedorn C,
Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C:
Re-directed T cells for the treatment of fibroblast activation
protein (FAP)-positive malignant pleural mesothelioma
(FAPME-1). BMC Cancer 2012, 12:615.) is designed to test
the safety of FAP-specific re-directed T cells after injection
in the pleural effusion, we developed an intra-peritoneal
model for the adoptive transfer of T cells to model
the function of these cells in a body cavity. As shown by
June and coworkers for mesothelin-specific re-directed T
cells [35], the application of FAP-specific re-directed T cells
resulted in the specific lysis of the respective target cells.
Since the chosen model system tested human CD8 positive
cells in a murine xenograft model with human tumor cells,
the potential for allogeneic effects is a major concern. To
control for this allogeneic effect, we used our previously,
extensively characterized HLA-A*02:01/NY-ESO-1157-165
peptide-specific re-directed T cells because these cells
displayed some allogeneic reactivity [12]. Importantly,
HLA-A*02:01/NY-ESO-1157-165 peptide-specific re-directed
T cells could not control the growth of FAP + tumor cells
demonstrating the antigen-specific therapeutic effect of our
re-directed FAP-specific T cells.
Adoptive transfer of T cells with a new specificity gener-
ated by gene transfer is associated with two major con-
cerns. First, the new specificity can cause on-target off-site
effects resulting in T-cell mediated organ damage as docu-
mented by recent publications [36]. Therefore, the explor-
ation of off-site target expression is of crucial interest. In
healthy tissue, low-level expression of FAP could only be
detected in pancreas, placenta, cervix and uterus. We have
not tested tissue from chronically inflamed tissue. Chronic
inflammation of tissues causes activation of fibroblasts
as part of the remodeling process which occurs during
inflammation [18]. To estimate the effect of re-directed
FAP-specific T cells in chronically inflamed tissue, we used
activated fibroblasts from patients with rheumatoid arth-
ritis out of the effusion from inflamed joints. As reported,
the herein used activated fibroblasts isolated from different
donors expressed FAP [37]. Therefore, the strong and
antigen-specific lysis of fibroblasts derived from inflamed
tissue by re-directed FAP-specific T cells was expected.
This observation indicates the potential for adverse off-site
effects in tissues with activated fibroblasts. The F19 CAR
cannot be used in murine models of inflammation since
the scFv only recognizes the human version of FAP. Since
no other model for toxicity estimation is available with the
F19 CAR we performed cytotoxicity assay with human
fibroblast and implemented strict exclusion criteria for our
planed clinical study. All patients with chronic inflamma-
tory diseases have been excluded. Patients with coronary
heart disease (CHD), stroke or peripheral vascular disease
(PVD) also have to be excluded since expression of FAP
was detected in atherosclerotic vessels [31,38,39].
To further minimize potential long-term off-target tox-
icity we evaluated the therapeutic potential of a second
generation CAR with a CD28 co-stimulatory domain. We
and other have seen, that re-directed CD8+ T cells with
CAR containing a CD28 moiety eliminated target cells
more effectively than re-directed T cells with a CD3 do-
main alone [12,40]. CD28 signaling also induces IL-2
production, which leads to expansion of cells [41]. The
herein used CAR lacks the lck domain, avoiding IL-2 in-
duction [23]. The co-stimulation by 4-1BB also enhances
persistence and clonal expansion of re-directed T cells,
whereas cytotoxic activity is less impacted [42]. Based on
the most recent literature we designed a FAP-specific
CAR causing cell lysis by CD8+ T cells and minimal
long-term persistence. Based on the existing experience
this allows a clinical phase I trial to first test a CAR rec-
ognizing FAP, for which no clinical data are available so
far [6].
The second concern is the gene transfer itself. The clin-
ical course of patients with X-linked immunodeficiency
after gene transfer in hematopoietic stem cells resulted in
the development of leukemia in 4 out of 9 cases [43]. Most
recently, the safety of retroviral gene transfer in T cells in
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clinical settings was confirmed by measuring 540 patient
years of follow up [44]. During this time, retroviral gene
transfer resulted in no malignant transformation even in
cases with very high numbers of integrations per cell
(2x1011 integration site per cell). These recent data suggest
that T cells can be safely transduced by retroviral transfer.
Additionally, our re-directed FAP-specific T cells showed
limited in vitro survival in the absence of exogenous IL-2
suggesting that retroviral transduction did not result in
altered survival control. The limited life span implies a
predominant effector phenotype of terminally differenti-
ated T cells as was previously shown for HLA-A*02:01/
NY-ESO-1157-165 re-directed T cells [12]. These data also
suggest that gene transfer did not alter this differentiation
program of T cells allowing them to develop in functional
effector T cells.
Conclusion
Taken together, the presented data give a strong ration-
ale to test re-directed FAP-specific T cells in patients
with MPM since in vitro and in vivo functionality was
clearly demonstrated and FAP expression is present in
all subtypes of MPM. However, special caution is neces-
sary in the selection of patients. Patients with chronic in-
flammatory diseases should be excluded when targeting
FAP + tumors with FAP-specific re-directed T cells. Based
on these data, we recommend the adoptive transfer of re-
directed T cells in a loco-regional fashion to minimize im-
mediate systemic distribution and unexpected recognition
of FAP in off-site tissues. As loco-regional therapy, adop-
tive transfer could be performed in body cavities like pleura
or peritoneum or directly in the tumor tissue [45]. This
approach could also lead to a reduction of the number
of adoptively transferred cells resulting in small scale
production of re-directed T cells with reduced costs and
fewer technical hurdles for GMP production. Due to the
expression pattern of FAP in malignant tissues FAP spe-
cific re-directed T cells have the potential to demonstrate
anti-tumor effects besides MPM in a wide variety of dif-
ferent cancers.
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